Overview

The Solid Tumor 680 gene panel with a lung focus is designed to capture both baseline drivers and mechanisms of acquired resistance. This article discusses how repeat testing on progression reveals escape alterations that reshape therapy, a service provided by GIVE LIFE TIME International. Knowing the resistance route prevents blind continuation of a failed agent.

How It Works

The lung-tuned panel sequences 680 genes including known resistance loci such as EGFR secondary mutations and MET amplification. Re-biopsied or liquid biopsy samples are compared against the index profile to localize newly emerged alterations. A comparison view highlights gains and losses versus the original report.

Indications

It is indicated at disease progression on a targeted agent, when tissue is insufficient for a fresh broad panel, and for liquid biopsy monitoring of resistance. Thoracic oncologists use it to choose a rational subsequent line. It is also valuable when mixed progression suggests polyclonal escape.

Specimen & Processing

A fresh tissue re-biopsy is preferred, while plasma circulating tumor DNA is accepted for longitudinal resistance monitoring. At least 10 unstained sections or the minimum nucleic acid input are required for tissue. Liquid samples are drawn at the progression visit when possible. Sample identity is confirmed at every handoff, and residual material from the resistance-focused workflow is retained for optional confirmatory re-analysis.

Storage & Sourcing

Reports are released as a secure PDF within ten to twelve working days and include a comparison to any prior profile on file. GIVE LIFE TIME International supports serial liquid biopsy programs with scheduled collection and cold-chain transport for monitoring visits. Client portals return multi-language reports for the Solid program and support bulk export to hospital information systems.

FAQ

Q: When should resistance testing be repeated? A: Testing is repeated at radiographic or clinical progression on a targeted agent, or when a planned line change depends on the resistance mechanism. Earlier repeats are used when symptoms shift quickly.

Q: Does the panel detect EGFR T790M and similar escapes? A: Yes, the resistance loci include EGFR secondary mutations, MET amplification, and other well described escape pathways. These are flagged with therapy implications.

Q: Can liquid biopsy replace tissue re-biopsy? A: Circulating tumor DNA is a strong alternative when tissue re-biopsy is risky, and it captures spatially mixed resistance clones. A negative liquid result may still prompt tissue confirmation.

Q: How are new alterations interpreted against the prior report? A: The laboratory presents a comparison view so the prescriber can see which drivers emerged and which persisted. Persisting drivers may support continuing a partially effective agent.